Redox proteomic identification of 4-Hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: Insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease

Neurobiology of Disease

Volumn 30, Issue 1, 2008, Pages 107-120

  Reed, Tanea ^a   Perluigi, Marzia ^a,b   Sultana, Rukhsana ^a   Pierce, William M ^c   Klein, Jon B ^d   Turner, Delano M ^c   Coccia, Raffaella ^b   Markesbery, William R ^a,e   Butterfield, D Allan ^a,e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^d University of Louisville School of Medicine   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

Author keywords

4 hydroxynonenal; Alzheimer's disease; HNE; Lipid peroxidation; Mild cognitive impairment; Redox proteomics

Indexed keywords

4 HYDROXYNONENAL; ACTIN; ALPHA ENOLASE; BRAIN PROTEIN; CARBONYL REDUCTASE; ELONGATION FACTOR TU; HEAT SHOCK PROTEIN 70; INITIATION FACTOR; LACTATE DEHYDROGENASE; NEUROPEPTIDE; PHOSPHOGLYCERATE KINASE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

AGED; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMNESIA; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; EARLY DIAGNOSIS; ENZYME ACTIVITY; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; LIPID PEROXIDATION; MALE; MASS SPECTROMETRY; NEUROPATHOLOGY; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PARIETAL LOBE; PRIORITY JOURNAL; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; AGED; AGED, 80 AND OVER; ALDEHYDES; ALZHEIMER DISEASE; BRAIN; BRAIN CHEMISTRY; COGNITION DISORDERS; DISEASE PROGRESSION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LIPID PEROXIDATION; MALE; OXIDATION-REDUCTION; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRYPSIN;

EID: 40849120274     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.12.007     Document Type: Article

References (80)

1. Akman S.A., et al. Mapping oxidative DNA damage and mechanisms of repair. Ann. N. Y. Acad. Sci. 899 (2000) 88-102
2. Aksenov M., et al. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74 (2000) 2520-2527
3. Apostolova L.G., et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. Arch. Neurol. 63 (2006) 693-699
4. Bains J.S., and Shaw C.A. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Brain Res. Rev. 25 (1997) 335-358
5. Balcz B., et al. Increased brain protein levels of carbonyl reductase and alcohol dehydrogenase in Down syndrome and Alzheimer's disease. J. Neural Transm., Suppl. (2001) 193-201
6. Battaini F., et al. Protein kinase C anchoring deficit in postmortem brains of Alzheimer's disease patients. Exp. Neurol. 159 (1999) 559-564
7. Boguski M.S., and McIntosh M.W. Biomedical informatics for proteomics. Nature 422 (2003) 233-237
8. Boyd-Kimball D., et al. Proteomic identification of proteins oxidized by Abeta(1-42) in synaptosomes: implications for Alzheimer's disease. Brain Res. 1044 (2005) 206-215
9. Boyd-Kimball D., et al. Proteomic identification of proteins specifically oxidized in Caenorhabditis elegans expressing human Abeta(1-42): implications for Alzheimer's disease. Neurobiol. Aging 27 (2006) 1239-1249
10. Butterfield D.A., et al. Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide. Trends Mol. Med. 7 (2001) 548-554
11. Butterfield D.A., et al. Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death. Neurobiol. Aging 23 (2002) 655-664
12. Butterfield D.A., et al. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration. J. Neurochem. 86 (2003) 1313-1327
13. Butterfield D.A., et al. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. 22 (2006) 223-232
14. Butterfield D.A., et al. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci. Lett. 397 (2006) 170-173
15. Butterfield D.A., et al. Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. 1148 (2007) 243-248
16. Butterfield D.A., et al. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43 (2007) 658-677
17. Butterfield D.A., and Stadtman E.R. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 2 (1997) 161-191
18. Butterfield D.A., and Lauderback C.M. Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. 32 (2002) 1050-1060
19. Calabrese V., et al. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25 (2003) 437-444
20. Castegna A., et al. Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic. Biol. Med. 33 (2002) 562-571
21. Castegna A., et al. Proteomic identification of nitrated proteins in Alzheimer's disease brain. J. Neurochem. 85 (2003) 1394-1401
22. Chang R.C., et al. Phosphorylation of eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal degeneration in Alzheimer's disease. Neuroreport 13 (2002) 2429-2432
23. Davies P., and Terry R.D. Cortical somatostatin-like immunoreactivity in cases of Alzheimer's disease and senile dementia of the Alzheimer type. Neurobiol. Aging 2 (1981) 9-14
24. Davis B.M., et al. Clinical studies of the cholinergic deficit in Alzheimer's disease. I. Neurochemical and neuroendocrine studies. J. Am. Geriatr. Soc. 33 (1985) 741-748
25. Ding Q., et al. Ribosome dysfunction is an early event in Alzheimer's disease. J. Neurosci. 25 (2005) 9171-9175
26. Ding Q., et al. Decreased RNA, and increased RNA oxidation, in ribosomes from early Alzheimer's disease. Neurochem. Res. 31 (2006) 705-710
27. Doorn J.A., et al. Human carbonyl reductase catalyzes reduction of 4-oxonon-2-enal. Biochemistry 43 (2004) 13106-13114
28. Drake J., et al. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci. Lett. 356 (2004) 155-158
29. Duan Z., et al. Overexpression of human phosphoglycerate kinase 1 (PGK1) induces a multidrug resistance phenotype. Anticancer Res. 22 (2002) 1933-1941
30. Esterbauer H., et al. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
31. Ferrer I. Differential expression of phosphorylated translation initiation factor 2 alpha in Alzheimer's disease and Creutzfeldt-Jakob's disease. Neuropathol. Appl. Neurobiol. 28 (2002) 441-451
32. Goldman J.E. Immunocytochemical studies of actin localization in the central nervous system. J. Neurosci. 3 (1983) 1952-1962
33. Hayashi A., et al. Application of an automatic oxygenation technique to analysis of oxygen equilibrium curves for hemoglobinopathic red cells and functional screening of clinically important hemoglobinopathies. Hemoglobin 3 (1979) 429-450
34. Hensley K., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65 (1995) 2146-2156
35. Jouvenceau A., et al. Alteration of NMDA receptor-mediated synaptic responses in CA1 area of the aged rat hippocampus: contribution of GABAergic and cholinergic deficits. Hippocampus 8 (1998) 627-637
36. Keller J.N., et al. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64 (2005) 1152-1156
37. Kida K., et al. Gluconeogenesis in the kidney in vivo in fed rats. Circadian change and substrate specificity. J. Biochem. (Tokyo) 91 (1982) 755-760
38. Korenberg J.R., et al. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am. J. Hum. Genet. 50 (1992) 294-302
39. Lemieux N., et al. Human carbonyl reductase (CBR) localized to band 21q22.1 by high-resolution fluorescence in situ hybridization displays gene dosage effects in trisomy 21 cells. Genomics 15 (1993) 169-172
40. Levine R.L., et al. Carbonyl assays for determination of oxidatively modified proteins. Methods Enzymol. 233 (1994) 346-357
41. Li X., et al. Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport 15 (2004) 2237-2240
42. Ling M., et al. The human mitochondrial elongation factor tu (EF-Tu) gene: cDNA sequence, genomic localization, genomic structure, and identification of a pseudogene. Gene 197 (1997) 325-336
43. Magrane J., et al. Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. J. Neurosci. 24 (2004) 1700-1706
44. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997) 134-147
45. Masliah E., et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci. Lett. 174 (1994) 67-72
46. Maurer H.H., and Peters F.T. Toward high-throughput drug screening using mass spectrometry. Ther. Drug Monit. 27 (2005) 686-688
47. Montine T.J., et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic. Biol. Med. 33 (2002) 620-626
48. O'Brien J.S., and Sampson E.L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. J. Lipid Res. 6 (1965) 537-544
49. Ojika K., et al. NMDA receptor activation enhances the release of a cholinergic differentiation peptide (HCNP) from hippocampal neurons in vitro. Brain Res. Dev. Brain Res. 106 (1998) 173-180
50. Okada K., et al. 4-Hydroxy-2-nonenal-mediated impairment of intracellular proteolysis during oxidative stress. Identification of proteasomes as target molecules. J. Biol. Chem. 274 (1999) 23787-23793
51. Orrenius S., et al. Mitochondria as the focus of apoptosis research. Cell Death Differ. 4 (1997) 427-428
52. Pamplona R., et al. Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J. Biol. Chem. 280 (2005) 21522-21530
53. Perluigi M., et al. Proteomic analysis of 4-hydroxy-2-nonenal-modified proteins in G93A-SOD1 transgenic mice-a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med. 38 (2005) 960-968
54. Perluigi M., et al. Proteomic analysis of protein expression and oxidative modification in r6/2 transgenic mice: a model of Huntington disease. Mol. Cell Proteomics 4 (2005) 1849-1861
55. Perry E.K., et al. Cholinergic receptors in cognitive disorders. Can. J. Neurol. Sci. 13 (1986) 521-527
56. Pestova T.V., and Hellen C.U. The structure and function of initiation factors in eukaryotic protein synthesis. Cell Mol. Life Sci. 57 (2000) 651-674
57. Petersen R.C. Mild cognitive impairment clinical trials. Nat. Rev. Drug Discov. 2 (2003) 646-653
58. Poon H.F., et al. Quantitative proteomics analysis of specific protein expression and oxidative modification in aged senescence-accelerated-prone 8 mice brain. Neuroscience 126 (2004) 915-926
59. Poon H.F., et al. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice-a model of familial Parkinson's disease. Neurobiol. Dis. 18 (2005) 492-498
60. Poon H.F., et al. Quantitative proteomics analysis of differential protein expression and oxidative modification of specific proteins in the brains of old mice. Neurobiol. Aging 27 (2006) 1010-1019
61. Poot M., et al. Reversible inhibition of DNA and protein synthesis by cumene hydroperoxide and 4-hydroxy-nonenal. Mech. Ageing Dev. 43 (1988) 1-9
62. Pratico D., et al. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59 (2002) 972-976
63. Rossor M.N., et al. Cholinergic deficit in frontal cerebral cortex in Alzheimer's disease is age dependent. Lancet 2 (1981) 1422
64. Sajdel-Sulkowska E.M., and Marotta C.A. Alzheimer's disease brain: alterations in RNA levels and in a ribonuclease-inhibitor complex. Science 225 (1984) 947-949
65. Schonberger S.J., et al. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. Proteomics 1 (2001) 1519-1528
66. Skinner E.R., et al. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 116 Pt 3 (1993) 717-725
67. Subramaniam R., et al. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortical synaptosomal membrane proteins. J. Neurochem. 69 (1997) 1161-1169
68. Sultana R., and Butterfield D.A. Oxidatively modified GST and MRP1 in Alzheimer's disease brain: implications for accumulation of reactive lipid peroxidation products. Neurochem. Res. 29 (2004) 2215-2220
69. Sultana R., et al. Redox proteomics identification of oxidatively modified proteins in Alzheimer's disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J. Chromatogr., B, Analyt. Technol. Biomed. Life Sci. 833 (2006) 3-11
70. Sultana R., et al. Identification of nitrated proteins in Alzheimer's disease brain using a redox proteomics approach. Neurobiol. Dis. 22 (2006) 76-87
71. Tamagno E., et al. H2O2 and 4-hydroxynonenal mediate amyloid beta-induced neuronal apoptosis by activating JNKs and p38MAPK. Exp. Neurol. 180 (2003) 144-155
72. Thompson J.E., et al. Regulation of senescence by eukaryotic translation initiation factor 5A: implications for plant growth and development. Trends Plant Sci. 9 (2004) 174-179
73. Thongboonkerd V., et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 62 (2002) 1461-1469
74. Tome M.E., et al. Excess putrescine accumulation inhibits the formation of modified eukaryotic initiation factor 5A (eIF-5A) and induces apoptosis. Biochem. J. 328 Pt 3 (1997) 847-854
75. Uchida K. 4-Hydroxy-2-nonenal: a product and mediator of oxidative stress. Prog. Lipid Res. 42 (2003) 318-343
76. Vayssiere J.L., et al. Participation of the mitochondrial genome in the differentiation of neuroblastoma cells. In Vitro Cell. Dev. Biol. 28A (1992) 763-772
77. Williams T.I., et al. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol. Aging 27 (2006) 1094-1099
78. Xie C., et al. Expression of glutathione-S-transferase isozyme in the SY5Y neuroblastoma cell line increases resistance to oxidative stress. Free Radic. Biol. Med. 31 (2001) 73-81
79. Zheng J., and Ramirez V.D. Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex. Biochem. Biophys. Res. Commun. 261 (1999) 499-503
80. Zhu X., et al. Oxidative imbalance in Alzheimer's disease. Mol. Neurobiol. 31 (2005) 205-217